Reid Hoffman, Co-Founder, Board Chair at Manas AI shared a post on LinkedIn:
“There are 18,000 human diseases, yet 14,000 of them don’t have a single approved treatment. AI might be able to change that, today.
The way we discover and deliver treatments is slow, expensive, and siloed. The consequence is that potential treatments that might help in ‘unrelated’ diseases rarely become hypotheses anyone seriously tests, because no one is set up to connect those dots.
David Fajgenbaum, MD, MBA, MSc, and Every Cure are building AI tools to change that. AI is good at sifting through huge volumes of scientific and clinical information and connecting findings that sit in different corners of the research world.
That’s why Every Cure is building a giant database to compare all ~4,000 FDA-approved drugs against all ~18,000 diseases, then prioritize which ones look most worth testing. The goal is to narrow the field and open the data so researchers and clinicians can move faster on the best candidates.
You can also see the broader implications of Dr. Fajgenbaum’s work. If you can surface links between medicines and diseases that don’t sit in the same clinical ‘lane’, you can start to reduce the fragmentation that defines modern healthcare. Hopefully, that body of work leads to more humans getting access to better healthcare more quickly.
And in a moment when a lot of AI commentary defaults to dread, projects like Every Cure are a needed counterweight. A clear story about how AI tools, even in their infancy, can provide results for humanity.”
Other articles about AI on OncoDaily.